<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906304</url>
  </required_header>
  <id_info>
    <org_study_id>UNRC940401/18</org_study_id>
    <nct_id>NCT04906304</nct_id>
  </id_info>
  <brief_title>Comparison of Safety and Efficacy of de Novo Everolimus</brief_title>
  <official_title>Comparison of Safety and Efficacy of de Novo Everolimus Plus Low Dose of Cyclosporine With Standard Dose of Cyclosporine Plus Cellcept on CMV and BK Virus Infections Prevention in Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nowadays, de novo everolimus regimen in renal transplant patients is considered for reduction&#xD;
      of cyclosporine dose and it is mentioned that this regimen not only has similar safety and&#xD;
      efficacy, but also could prevent Cytomegalovirus (CMV )infections. So, the aim of this study&#xD;
      was comparison of safety and efficacy of de novo everolimus plus low dose of cyclosporine&#xD;
      with standard dose of cyclosporine plus cellcept on CMV virus infections prevention in renal&#xD;
      transplant patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized clinical trial was conducted in Shahid Labbafi nejad hospital. 35 renal&#xD;
      transplanted patients enter the study and randomized to one of two groups: everolimus or&#xD;
      control (Sandimmun or tacrolimus). However, 34 patients completed study (17 patients in each&#xD;
      group). The treatment regimen in everolimus group was 0.75 mg/bid everolimus with everolimus&#xD;
      C0 3-8 ng/mL plus Sandimmun (Neoral) low dose and in control group was standard dose of&#xD;
      Sandimmun or tacrolimus plus cellcept. All patients gave Antithymocyte Glubolin and&#xD;
      prednisolone. In addition, they gave CMV prophylaxis until 3 months. Kidney biopsies were&#xD;
      done for raise of creatinine or protocol biopsy at 6 month after transplantation.&#xD;
      Demographic, renal disease and transplantation characteristics, CMV and BK virus status,&#xD;
      rejection, and routine laboratory tests recorded during study period and compared between two&#xD;
      groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CMV Infection</measure>
    <time_frame>6 months</time_frame>
    <description>CMV PCR quantitative count</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Evrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment regimen in everolimus group was 0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral) low dose pluse cellcept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral)standard dose plus cellcept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus Pill</intervention_name>
    <description>standard dose versus low dose Sandimun</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Evrolimus</arm_group_label>
    <other_name>Novartis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sandimmun (Neoral) dose plus cellcept</intervention_name>
    <description>Sandimmun (Neoral) dose plus cellcept</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Evrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Transplanted patients &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Simultanous Kidney -Pancreas Transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SBMU University of Medical Sciences</last_name>
    <role>Study Director</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nooshin Dalili</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>nooshin dalili</investigator_full_name>
    <investigator_title>assistant Professor of SBMU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

